GSK First Quarter 2025 Performance Report
Issued: Wednesday,30 April 2025, London, U.K. GSK makes strong start to 2025 with growth in sales, profits and earnings Specialty Medicines growth drives Q1 performance • Total Q1 sales £7.5 billion +2% AER; +4% CER • Specialty Medicines sales £2.9 billion (+17%); Respiratory, Immunology and Inflammation £0.8 billion (+28%); Oncology £0.4 billion (+53%); HIV sales £1.7 billion (+7%) • Vaccines sales £2.1 billion (-6%); Shingrix £0.9 billion (-7%); Meningitis vaccines £0.4 billion (+2...
